admin – Page 2767 – Get News Story

Codex Labs Shaant Skin De-Stress Supplement 2.0 for Female Hormonal Acne Is Launched with Clinical Study Results

San Jose, CA. – July 10th, 2025 – Codex Labs, a Silicon Valley skintech company, announced the launch of its second-generation Shaant De-Stress Myo-Inositol-based Herbal Supplement for managing female hormonal acne.

“At Codex Labs, we are focused on studying the interactions between skin-gut-brain-microbiome axes and hormonal imbalance or gut dysbiosis, to develop next-generation solutions for skin conditions such as acne,” says Dr. Barbara Paldus, CEO, Codex Labs. “These new systems will require integration of topicals with core supplements, diet, lifestyle, and mental health, to achieve optimum clearance.”

The Shaant Skin De-Stress Supplement was formulated in partnership with Dr. Jessica Maloh, N.D., an integrative naturopathic doctor, and Dr. Raja Sivamani, an integrative board-certified dermatologist and Ayurvedic practitioner.

“Research suggests that myo-inositol, a dietary supplement, may be helpful for PCOS-related acne,” says Dr. Maloh. “The mechanism of action may be related to its ability to lower androgen levels and support healthy glucose metabolism. However, to address other contributors and aggravators to acne, we wanted to formulate a supplement that also addresses gut health, psychological stress, and inflammation.”

The Shaant Skin De-Stress Supplement 2.0 is formulated with herbal and active ingredients designed to support hormonal balance (myo-inositol), metabolic health (milk thistle, barberry, myo-inositol), and psychological stress relief (l-theanine and holy basil), while improving gut microbiome diversity and managing the acne inflammasome (MSM and turmeric).

In an independent clinical trial at Integrative Skin Science and Research involving 36 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Shaant Skin De-Stress Herbal Supplement use included:

61% reduction in inflammatory lesions
62% reduction in non-inflammatory lesions
52% decrease in aldosterone hormone
184% increase in butyric acid for gut barrier integrity

Significant reductions in estrone, 17-OHP, and androstenedione suggested notable effects on steroid hormone metabolism. Progesterone also showed a consistent downward trend across both time points in the study. Complete results are published in Dermatology and Therapy (https://link.springer.com/article/10.1007/s13555-025-01411-4).

All products are manufactured in a high-tech, cGMP-compliant facility, and each batch is third-party tested to ensure the highest quality.

About Codex Labs

Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Our products are focused on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable dermaceutical solutions.

Media Contact
Company Name: Otter Public Relations
Contact Person: Anna Kate Womack
Email: Send Email
Phone: 7032323140
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Codex Labs Shaant Skin De-Stress Supplement 2.0 for Female Hormonal Acne Is Launched with Clinical Study Results

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight

“KRAS Inhibitors Drugs Market”

KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others

(Albany, USA) In 2024, the United States held nearly 70% of the KRAS inhibitors market across the 7MM, driven by a high burden of KRAS-mutated cancers, especially NSCLC, which accounts for 46% of such cases in the region. KRAS, the most commonly mutated RAS gene, is linked to pancreatic, colorectal, lung, and ovarian cancers. While current therapies mainly target the G12C mutation, newer pan-KRAS approaches, like onvansertib, aim to treat multiple KRAS variants, broadening patient reach. Key players include Roche, Revolution Medicines, Eli Lilly, Merck, AstraZeneca, and Cardiff Oncology, intensifying efforts to develop therapies for hard-to-treat KRAS mutations such as G12D.

The report titled “KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast- 2034” by DelveInsight provides a comprehensive analysis of KRAS Inhibitors. It presents a detailed overview of the historical and projected epidemiological data, along with the market trends for KRAS Inhibitors in the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report on the KRAS Inhibitors market offers up-to-date treatment methods, upcoming medications, the market share of different therapies, and the present as well as projected size of the KRAS Inhibitors market from 2020 to 2034. The market is divided into seven major segments. Additionally, the report examines the existing treatment practices and strategies for KRAS Inhibitors, factors driving market growth, obstacles encountered, and medical needs that have yet to be addressed. This comprehensive assessment aims to identify the most promising opportunities and evaluate the inherent potential of the KRAS Inhibitors market.

Download DelveInsight’s comprehensive KRAS Inhibitors Market Report to explore evolving treatment landscapes, emerging therapies, and future opportunities @ KRAS Inhibitors Market

Some facts of the KRAS Inhibitors Market Report are:

According to DelveInsight, KRAS Inhibitors market size is expected to grow at a decent CAGR by 2034.
Leading KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
Promising KRAS Inhibitors Therapies expected to launch in the market are LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), JDQ443, Divarasib, and others.
On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
In April 2025, Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initiate a Phase 1/2a study in mid-2025 with plans for multiple expansion cohorts, including combinations, in advanced solid tumors, such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
In January 2025, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company at the forefront of developing innovative oral therapies for RAS-driven cancers, announced advancements in its pipeline of KRAS-directed drug candidates. This includes the clearance of a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application for QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor, which allows the initiation of a Phase 1 clinical trial.
In June 2024, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing innovative oral treatments for RAS-driven cancers, announced the progress of two clinical trials from its pipeline of KRAS-directed drug candidates. The first patient has been dosed in the monotherapy phase of a Phase 1 trial evaluating QTX3046, a KRASG12D-selective inhibitor. Additionally, patient dosing has commenced in the combination phase of the ongoing Phase 1 trial assessing QTX3034, a multi-KRAS inhibitor that preferentially targets G12D, in combination with cetuximab. Both trials are enrolling patients with KRASG12D-mutated advanced solid tumors.
In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the treatment of KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.
In April 2023, BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
In May 2023, Mirati Therapeutics announced Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients.
In Jan 2023, Pfizer and Array BioPharma announced the Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

KRAS Inhibitors Overview

KRAS inhibitors are a specific form of targeted therapy devised to hinder the function of the KRAS gene, which plays a vital role in numerous types of cancer. The KRAS gene is part of a gene family called RAS genes and is responsible for regulating cellular division and growth. Mutations in the KRAS gene can prompt uncontrolled cell growth and division, ultimately leading to the formation of cancer.

Traditionally, it has been challenging to address KRAS mutations using conventional treatments, making KRAS-driven cancers particularly difficult to manage. However, considerable advancements have been made in recent years with the development of KRAS inhibitors that effectively impede the abnormal activity of mutated KRAS proteins. These inhibitors are specifically designed to target the altered KRAS protein, aiming to disrupt its signalling pathways and hinder the growth of cancerous cells.

Discover which KRAS inhibitors are set to transform oncology care. Get your free sample report now! @ KRAS inhibitors Treatment Market

KRAS Inhibitors Market

The KRAS Inhibitors market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted KRAS Inhibitors market trends by analyzing the impact of current KRAS Inhibitors therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the KRAS Inhibitors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated KRAS Inhibitors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the KRAS Inhibitors market in 7MM is expected to witness a major change in the study period 2020-2034.

KRAS Inhibitors Epidemiology

The KRAS Inhibitors epidemiology section provides insights into the historical and current KRAS Inhibitors patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the KRAS Inhibitors market report also provides the diagnosed patient pool, trends, and assumptions.

Access detailed epidemiology, patient trends, and forecast data through 2034. Request your tailored market intelligence report today! @ KRAS inhibitors Epidemiology Analysis

KRAS Inhibitors Drugs Uptake

The KRAS Inhibitors Drugs Uptake section emphasizes the rate at which the newly introduced KRAS Inhibitors medications in the market, or those projected to be launched between 2020 and 2034, are being adopted. The examination encompasses the adoption of drugs in the KRAS Inhibitors market, the acceptance of therapies by patients, and the sales figures for each medication.

KRAS Inhibitors Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on KRAS Inhibitors market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

KRAS Inhibitors Pipeline Development Activities

The KRAS Inhibitors report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses KRAS Inhibitors key players involved in developing targeted therapeutics.

Dive into the latest clinical developments, FDA/EMA approvals, and key players driving innovation in KRAS-targeted therapies @ KRAS inhibitors FDA Approvals and Clinical Trials

KRAS Inhibitors Therapeutics Assessment

Major key companies are working proactively in the KRAS Inhibitors Therapeutics market to develop novel therapies which will drive the KRAS Inhibitors treatment markets in the upcoming years are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.

Learn more about the emerging KRAS Inhibitors therapies & key companies @ KRAS inhibitors Medication and Therapies

KRAS Inhibitors Report Key Insights

1. KRAS Inhibitors Patient Population

2. KRAS Inhibitors Market Size and Trends

3. Key Cross Competition in the KRAS Inhibitors Market

4. KRAS Inhibitors Market Dynamics (Key Drivers and Barriers)

5. KRAS Inhibitors Market Opportunities

6. KRAS Inhibitors Therapeutic Approaches

7. KRAS Inhibitors Pipeline Analysis

8. KRAS Inhibitors Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the KRAS Inhibitors Market

Table of Contents

1. Key Insights

2. Executive Summary

3. KRAS Inhibitors Competitive Intelligence Analysis

4. KRAS Inhibitors Market Overview at a Glance

5. KRAS Inhibitors Disease Background and Overview

6. KRAS Inhibitors Patient Journey

7. KRAS Inhibitors Epidemiology and Patient Population

8. KRAS Inhibitors Treatment Algorithm, Current Treatment, and Medical Practices

9. KRAS Inhibitors Unmet Needs

10. Key Endpoints of KRAS Inhibitors Treatment

11. KRAS Inhibitors Marketed Products

12. KRAS Inhibitors Emerging Therapies

13. KRAS Inhibitors Seven Major Market Analysis

14. Attribute Analysis

15. KRAS Inhibitors Market Outlook (7 major markets)

16. KRAS Inhibitors Access and Reimbursement Overview

17. KOL Views on the KRAS Inhibitors Market

18. KRAS Inhibitors Market Drivers

19. KRAS Inhibitors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight

$33 Billion for Drones: How the One Big Beautiful Bill Creates a New Defense Boom (ZENA, KTOS, AVAV, LHX)

The One Big Beautiful Bill, also known as H.R. 1, was signed into law by President Trump on July 4, 2025. It delivers one of the largest federal investment packages in recent memory, combining permanent tax changes with over $150 billion in new defense spending and another $150 billion for border security, ICE, and related initiatives. Rather than broad stimulus, this law directs funds toward high-priority national capabilities with focused execution and firm timelines.

A standout allocation is the more than $33 billion in funding set aside for drone systems, autonomous platforms, and artificial intelligence technologies. That includes $13.5 billion for small uncrewed systems and autonomous weapons, $9 billion for collaborative combat aircraft, and nearly $3 billion for advanced surveillance and sensor platforms. The bill also supports U.S. drone manufacturing and federal certification through Blue UAS and Green UAS programs, which allow vetted companies to directly sell into military and homeland security channels.

Funding is structured to move fast. Although the total budget spans through 2034, initial pilot programs, procurement cycles, and R&D awards are expected within the next 12 months. That creates immediate opportunity for companies with proven drone hardware, scalable software, and national deployment capabilities. Use cases range from defense and border control to wildfire detection, agriculture, and smart logistics.

This is not a speculative theme. It is a policy-backed investment cycle that could reshape the U.S. drone landscape over the next decade. So where could this money actually land? Here are four stocks worth watching.

ZenaTech (Nasdaq: ZENA) is rapidly emerging as a key player in the next U.S. drone investment cycle, with strong alignment to the $33 billion in funding for drones, autonomy, and artificial intelligence systems under the One Big Beautiful Bill. The company, listed on the Nasdaq and dual-listed in Europe and Mexico, integrates proprietary drone platforms with quantum computing, enterprise software, and a fast-growing Drone as a Service (DaaS) business tailored to defense, government, and industrial customers.

The company’s momentum is driven by its wholly owned subsidiary, ZenaDrone, which develops autonomous uncrewed aerial systems for surveillance, inspection, delivery, and reconnaissance missions. Its flagship platform, the ZenaDrone 1000, is a rugged, medium-lift VTOL aircraft equipped with secure communications, AI-assisted navigation, and mission-ready ISR capabilities. It has already completed paid trials with the U.S. Air Force and Navy Reserve, delivering critical cargo such as blood supplies. This platform, along with others in the portfolio, is advancing through the Green UAS and Blue UAS certification processes required for federal and defense procurement.

ZenaTech’s broader drone lineup includes:

IQ Nano: A compact indoor drone designed for autonomous operations in GPS-denied environments. It supports inventory management, security patrols, and real-time facility monitoring, using AI-driven navigation and barcode or RFID scanning.
IQ Square: A versatile drone built for outdoor and indoor use in land surveying, infrastructure inspection, and mobile security missions.

Alongside its hardware offerings, ZenaTech is expanding its national Drone as a Service (DaaS) platform. The model allows clients to access drones through subscription or pay-per-use, including pilot services, maintenance, and full regulatory compliance. This structure is designed to streamline adoption for public and commercial sector users while providing flexibility and scalability as needs evolve.

Strategic Fit with Federal Funding

ZenaTech stands to benefit across several high-priority funding areas defined by the new legislation:

$13.5 billion allocated for small uncrewed aerial systems and autonomous platforms. Both the ZenaDrone 1000 and IQ Nano are positioned to meet demand in this segment.
$16 billion dedicated to military innovation programs, including funding for autonomous systems, reusable platforms, and next-generation AI. ZenaTech is actively pursuing partnerships through these initiatives.
Restoration of full R&D expensing and availability of 100 percent bonus depreciation through 2029, which supports the company’s reinvestment in advanced manufacturing, robotics, and AI drone technologies.

The company has also made significant moves to support its expansion:

ZenaTech recently completed multiple acquisitions of land survey and engineering firms. These are now integrated into the DaaS business, enabling drone-powered surveying and inspection services for defense and infrastructure projects across the Southeast, Northwest, and tribal territories.
Its Clear Sky initiative is building one of the first drone swarm and quantum computing platforms focused on wildfire prediction and environmental monitoring. Using AI-equipped drones with LiDAR and thermal sensors, the system collects massive volumes of geospatial data which are analyzed in real time through quantum models to simulate fire risk and weather behavior.
The IQ Nano is now being tested for swarm functionality in defense applications. Proprietary imaging and sensing systems developed in-house are enabling fully autonomous coordination for real-time situational awareness and security missions.

In the first quarter of 2025, ZENA reported a 92 percent increase in revenue compared to the previous year. That growth reflects a combination of acquisitions and organic expansion across both its drone and enterprise software segments. According to CEO Shaun Passley, Ph.D., current spending increases are intentional and focused on long-term returns in product development, manufacturing, and market penetration, areas that are now directly supported by new federal tax incentives.

ZenaTech (Nasdaq: ZENA) is more than a promising name in the drone space. It has operational momentum, revenue traction, and strategic fit across multiple facets of the new law. With federal certifications underway, a scalable DaaS model, and growing engagement in defense, wildfire resilience, and infrastructure modernization, ZenaTech is positioned to capture meaningful share as public funding accelerates deployment across the U.S. drone ecosystem.

Kratos Defense & Security Solutions (Nasdaq: KTOS) is a proven player with a mature pipeline of military-grade autonomous systems. Its portfolio spans tactical drones, loitering munitions, AI-enabled ground convoys, and full C5ISR platforms. Flagship products include the XQ-58A Valkyrie, autonomous ground vehicles, and hypersonic propulsion systems used in multiple Department of Defense programs.

Kratos recently announced a new 100,000-square-foot engine facility in Oklahoma to support its GEK-series jet engines. This production capacity will support five lines and up to 500 engines annually, accelerating its ability to scale as new contracts roll out. The plant is state-backed and tied directly to defense propulsion needs.

In June, Kratos raised $556 million in equity capital to support national security priorities and large program expansion. CEO Eric DeMarco said Kratos is “uniquely positioned” for what he described as a generational recapitalization of advanced weapon systems. The company reported $302.6 million in revenue in Q1 2025, a book-to-bill ratio of 1.2, and $1.5 billion in total backlog with $12.6 billion in active proposals.

With a history of federal partnerships, certified systems, and active manufacturing expansion, Kratos stands to benefit from the bill’s direct funding for tactical drones and autonomy.

AeroVironment (Nasdaq: AVAV) enters this cycle with momentum, scale, and a deep bench of autonomous systems. Its product range includes Group 3 drones, loitering munitions, counter-UAS technologies, and multi-domain ISR solutions. The company reported $1.2 billion in bookings for fiscal 2025, with a growing backlog and expectations to double revenue to as much as $2 billion in fiscal 2026.

Recent flight testing of Wildcat, a vertical takeoff drone developed under DARPA’s EVADE program, confirms its edge in contested environments. The aircraft has successfully completed propulsion validation and payload integration, with ISR applications in development.

AeroVironment’s acquisition of BlueHalo expanded its production scale and defense reach. The company also launched a $1.35 billion capital raise to fuel growth and repay debt. CEO Wahid Nawabi described the firm as “well positioned to meet rising global demand,” with integrated solutions across all domains.

With DARPA relationships, next-gen drone designs, and certified ISR capabilities, AeroVironment is directly aligned with the new procurement and R&D investments triggered by the bill.

L3Harris Technologies (NYSE: LHX) brings scale, reliability, and program depth across air, land, sea, space, and cyber systems. The company’s unmanned platforms are built for multi-domain defense missions and are already fielded across major U.S. government programs.

Earlier this year, L3Harris delivered the first mission-ready Skyraider II aircraft to U.S. Air Force Special Operations Command. The aircraft is designed for ISR, precision strike, and flexible battlefield roles. On the space front, the company is producing 34 satellites for federal missile defense and has five already in orbit. In Virginia, it is building five new solid rocket motor factories to expand domestic propulsion capacity.

L3Harris reported $5.1 billion in revenue in Q1 2025, with a 15.6 percent adjusted segment operating margin. It returned $800 million to shareholders through dividends and buybacks. CEO Christopher Kubasik emphasized the firm’s alignment with evolving federal security priorities.

With end-to-end systems, advanced R&D investments, and federal-grade reliability, L3Harris is built to absorb and execute against the bill’s historic drone and autonomy spending.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: $33 Billion for Drones: How the One Big Beautiful Bill Creates a New Defense Boom (ZENA, KTOS, AVAV, LHX)

MASH Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight

“MASH Market”

MASH Companies are Hepion Pharmaceuticals, Ionis Pharmaceuticals, Galectin Therapeutics, Novo Nordisk A/S, Cirius Therapeutics, HighTide Biopharma, Boehringer Ingelheim, Hepagene, Eli Lilly and Company, Pfizer, Lipocine, Corcept Therapeutics, Poxel SA, Enyo Pharmaceuticals, Akero Therapeutics, Zydus Therapeutics, 89bio, Viking Therapeutics, Boston Pharmaceuticals, Gilead Sciences, Merck & Co., Zealand Pharma, Hanmi Pharmaceutical, Inventiva Pharma, CytoDyn, Sagimet Biosciences, and others.

Metabolic dysfunction-associated Steatohepatitis Market Summary

According to DelveInsight, the MASH (Metabolic dysfunction-associated steatohepatitis) market across the 7MM (US, EU4, UK, Japan) was valued at approximately USD 1.8 billion in 2023 and is expected to grow at a robust CAGR of 24% from 2025 to 2034. In 2023, there were about 8 million diagnosed prevalent cases, with the US accounting for 55%, EU4 and the UK for 36%, and Japan for 9%. Market growth is fueled by rising prevalence driven by obesity, sedentary lifestyles, aging populations, and better disease awareness and diagnostics. Pipeline therapies like efruxifermin (EFX), VK2809, efimosfermin alfa, icosabutate, denifanstat, and pegozafermin are set to transform treatment. Currently, management focuses on lifestyle modifications, with REZDIFFRA (Resmetirom) being the only FDA-approved drug, specifically for noncirrhotic NASH with moderate to advanced fibrosis. Despite advancements, a therapeutic gap remains due to limited antifibrotic treatments that directly reverse fibrosis. Efruxifermin, now in Phase III trials, is anticipated to launch by 2027. Notably, Akero Therapeutics completed enrollment for the Phase III SYNCHRONY Real-World study of EFX in January 2025, with results expected in early 2026, which could further shape the future treatment landscape of MASH.

(Albany, USA) DelveInsight’s Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

The MASH market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted MASH market size from 2020 to 2034, segmented by seven major markets. The Report also covers current MASH treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the MASH market.

Explore DelveInsight’s latest analysis on market trends, pipeline therapies, and future projections across the 7MM. Download the full MASH Market Report now and uncover key insights driving growth through 2034. @ @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

The total MASH market size in the 7MM was approximately USD 2,114 million in 2023 and is projected to increase during the forecast period (2024–2034).

In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM.
Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years.
The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others.
In May 2025, Novo Nordisk revealed plans to showcase new findings from its metabolic and cardiovascular portfolio at the 32nd European Congress on Obesity (ECO), scheduled for May 11–14, 2025. Highlights will include real-world evidence on semaglutide, further analyses from the SELECT cardiovascular outcomes trial, and results from part 1 of the phase 3 ESSENCE trial targeting metabolic dysfunction-associated steatohepatitis (MASH).

In May 2025, Roche introduced the Elecsys® PRO-C3 test, a novel diagnostic tool aimed at evaluating liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Developed in partnership with Nordic Bioscience, this test offers healthcare providers a straightforward and effective method to detect varying degrees of liver fibrosis, supporting prompt intervention and disease management.
In January 2025, Akero Therapeutics completed enrolment for the double-blind portion of the Phase III SYNCHRONY Real-World study evaluating EFX in patients with MASH or MASLD (F1–F4). Results from the study are expected in the first half of 2026.
On November 1, 2024, Novo Nordisk reported encouraging outcomes for semaglutide in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Results from the Phase 3 Essence trial demonstrated that a once-weekly 2.4 mg dose of semaglutide led to improvements in liver fibrosis and resolution of steatohepatitis, without worsening existing fibrosis, in patients with stage 2 or stage 3 fibrosis—successfully achieving the primary endpoints.

On October 29, 2024, Sagimet Biosciences (SGMT) announced the successful completion of end-of-Phase 2 discussions with the FDA, clearing the path for denifanstat to progress into Phase 3 trials targeting MASH.
In March 2024, Madrigal Pharmaceuticals’ groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis.

Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report

Metabolic Dysfunction-Associated Steatohepatitis Overview

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer.

The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition.

MASH is often asymptomatic in its early stages. When MASH symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise.

MASH Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity.

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation

The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Prevalent Cases of MASH
Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH

MASH Treatment Market

The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients’ quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease.

The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient.

To know more about MASH treatment guidelines, visit @ Metabolic Dysfunction-Associated Steatohepatitis Management

Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies

Lanifibranor (IVA337): Inventiva Pharma
Semaglutide: Novo Nordisk A/S
Azemiglitazone (MSDC-0602K): Cirius Therapeutics
Efruxifermin (EFX): Akero Therapeutics
BIO89-100 (Pegozafermin): 89bio
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
GR-MD-02 (Belapectin): Galectin Therapeutics
LPCN1144: Lipocine
VK2809: Viking Therapeutics
Tirzepatide: Eli Lilly and Company
BOS-580: Boston Pharmaceuticals
Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer
HTD1801: HighTide Biopharma
Leronlimab (PRO 140): CytoDyn
Efinopegdutide: Merck & Co./Hanmi Pharmaceutical
HPG1860: Hepagene (Shanghai)
Rencofilstat (CRV431): Hepion Pharmaceuticals
EYP001 (Vonafexor): Enyo Pharmaceuticals
Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences
PXL065: Poxel SA
Saroglitazar Magnesium: Zydus Therapeutics
Denifanstat (TVB-2640): Sagimet Biosciences
ION224: Ionis Pharmaceuticals
Miricorilant (CORT118335): Corcept Therapeutics

Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials and Advancements

MASH Market Dynamics

The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation.

Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM.

However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA’s draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption.

Moreover, MASH treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth.

Download the report to understand which factors are driving MASH drugs and therapies in pipeline @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Metabolic Dysfunction-Associated Steatohepatitis CAGR: 17.9 %
Metabolic Dysfunction-Associated Steatohepatitis Market Size in 2023: USD 2.1 Billion
Key Metabolic Dysfunction-Associated Steatohepatitis Companies: Hepion Pharmaceuticals (NASDAQ: HEPG), Ionis Pharmaceuticals (NASDAQ: IONS), Galectin Therapeutics (NASDAQ: GALT), Novo Nordisk A/S (NYSE: NVO), Cirius Therapeutics (Private), HighTide Biopharma (TSX-V: HBT), Boehringer Ingelheim (Private), Hepagene (Private), Eli Lilly and Company (NYSE: LLY), Pfizer (NYSE: PFE), Lipocine (NASDAQ: LPCN), Corcept Therapeutics (NASDAQ: CORT), Poxel SA (EPA: POXEL), Enyo Pharmaceuticals (Private), Akero Therapeutics (NASDAQ: AKRO), Zydus Therapeutics (NSE: ZYDUSLIFE), 89bio (NASDAQ: ETNB), Viking Therapeutics (NASDAQ: VKTX), Boston Pharmaceuticals (Private), Gilead Sciences (NASDAQ: GILD), Merck & Co. (NYSE: MRK), Zealand Pharma (CPH: ZEAL), Hanmi Pharmaceutical (KRX: 128940), Inventiva Pharma (EPA: IVA), CytoDyn (OTCQB: CYDY), Sagimet Biosciences (NASDAQ: SGMT).
Key Pipeline Metabolic Dysfunction-Associated Steatohepatitis Therapies: Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others
Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies
Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. MASH Epidemiology and Patient Population

10. MASH Patient Journey

11. Marketed MASH Drugs

12. Emerging MASH Drugs

13. MASH Market Analysis

14. Key Opinion Leaders’ Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MASH Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight

After the Mic Drop: Why American Rebel (NASDAQ: AREB) Could Be the Most Underrated Brand Story in America

If you tuned into the recent live interview with American Rebel CEO Andy Ross—whether on X or in print—chances are, you came away with one conclusion: this isn’t your typical beverage company.

This is something bigger. Bolder. And far more timely. As the company puts it, “America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer.”

Following the full-length executive Q&A and a high-energy livestream event that brought out fans and investors, one thing has become crystal clear: American Rebel Holdings (NASDAQ: AREB) isn’t just selling a great beverage—it’s selling belief. And the market is starting to understand the magnitude of what that means.

A Brand With Grit, Not Gloss

If you haven’t heard of Rebel Light yet, that’s probably about to change. Less than a year old, the brand has already established a nationwide presence—with retail in 14 states, online shipping to 40+, and major distributors onboarding in real time.

But what’s driving the wave isn’t clever packaging or celebrity endorsement. It’s conviction. The kind you can’t fake.

“We’re not chasing the American dream—we’re canning it,” Ross said in a prior interview. “This brand wasn’t born in some corporate pitch deck. It was built in the trenches—on stage, on the road, in the heart of America.”

That authenticity is the differentiator. While legacy brands hedge, mute, and reposition to chase every trending topic, American Rebel planted a flag. The message isn’t subtle. It’s proudly God-fearing, Constitution-loving, and unapologetically patriotic. And millions of Americans are responding.

Rebel Light Is Winning Where It Counts

This isn’t just cultural momentum. It’s translating into serious traction across multiple channels.

On the retail side, American Rebel has landed 62-store authorization with Minuteman Food Marts across the Carolinas, secured placement in Total Wine & More, and expanded distribution across states like Ohio, Kansas, Kentucky, and Tennessee. Sales data from Nashville’s busiest bars suggests Rebel Light is now outselling traditional light beer competitors in many venues.

Online, the numbers are even harder to ignore. As Andy shared during the Q&A:

“Our website traffic jumped 4500%. Orders were up 1000%. Repeat purchases up 72%. We’re not just drawing attention—we’re earning loyalty.”

And that loyalty is spreading. The company’s Fourth of July campaign converted bulk orders across 40+ states. New customer acquisition was strong—but the surprise was the scale of repeat demand. People didn’t just want to try Rebel Light. They wanted it stocked. They wanted it cold and ready. They wanted more.

For a company this early in its brand lifecycle, that’s not just promising. It’s exceptional.

This Isn’t Just a Product Play—It’s a Culture Platform

If Andy Ross’s interview made anything clear, it’s that American Rebel isn’t just focused on selling a great beverage. The vision is far wider.

The company is already expanding into branded merchandise, with ambitions to launch grills, tailgate gear, tools, even dog food. “If it’s red, white, and built to last, it should say American Rebel on it,” Ross said.

It may sound audacious. But so did launching a beverage product in the most competitive segment of the beverage market—and getting it into bars on Broadway, title-sponsoring NHRA races, and outselling legacy brands at Charlotte Motor Speedway. And yet, that’s exactly what American Rebel has done.

This isn’t about building a product. It’s about building identity. A lifestyle. A tribe.

And that kind of brand gravity—the kind that makes people wear the logo, raise the can, and evangelize—is something few companies, public or private, ever capture.

The Small-Cap Opportunity Hiding in Plain Sight

Here’s the part the market still hasn’t fully priced in: American Rebel Holdings (NASDAQ: AREB) is still a microcap stock. The same company shipping thousands of 48-packs nationwide, pouring ice-cold at Kid Rock’s Big Ass Honky Tonk, and headlining concerts at NHRA events is still flying well below institutional radars.

But that won’t last forever. AREB has the feeling of a pre-Monster Energy moment.

The company already has production scalability locked in through a major manufacturer. It has growing brand awareness. It has regional and national distribution expanding quarter over quarter. And, most importantly, it has a fanbase that isn’t just buying the product—they’re buying into the brand.

This Isn’t a Trend. It’s a Turning Point

If you’re tracking the cultural tide, this isn’t hard to see: Americans want something real. They’re tired of being marketed to by brands that don’t reflect their values or respect their identity. American Rebel is filling that gap—with a great beverage, yes—but also with belief.

For investors, the opportunity here is clear. Rebel Light isn’t just riding a wave. It’s creating one. And if you’re looking for a small-cap story with real cultural firepower, operational traction, and long-term brand expansion potential—American Rebel may be your rare shot to catch it before Wall Street does.

Disclaimers: Hawk Point Media Group, Llc. (HPM) has created this sponsored advertorial content as part of a broader digital marketing program. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated ten-thousand-dollars via wire transfer in USD by American Rebel Holdings to create this content as part of a more extensive digital marketing program. Accordingly, this content may be used and syndicated beyond the channels used by Hawk Point Media, Llc. If so, this disclaimer and the link to the broader disclosures must be part of all reproductions. The compensation received creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in American Rebel Holdings. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: After the Mic Drop: Why American Rebel (NASDAQ: AREB) Could Be the Most Underrated Brand Story in America

Dynamic Family Therapy LLC Offers Comprehensive Mental Health Services in Honolulu

Comprehensive Mental Health Services in Honolulu Dynamic Family Therapy LLC is a Honolulu-based mental health practice dedicated to supporting individuals, couples, and families through evidence-based therapeutic services. With a compassionate, culturally sensitive approach, the clinic offers personalized counseling to promote healing, strengthen relationships, and enhance overall well-being.

July 10, 2025 – Honolulu, HI – With a strong emphasis on evidence-based practices and a compassionate approach, the clinic continues to serve the community by addressing a wide range of emotional and relational challenges.

Personalized Support for Mental Wellness

Dynamic Family Therapy LLC specializes in personalized, client-centered care designed to foster healing and growth. Licensed professionals deliver structured, confidential therapy sessions aimed at helping individuals manage anxiety, depression, trauma, and behavioral issues. Those seeking Counseling in Honolulu can find a supportive environment focused on building healthier lives.

Strengthening Relationships Through Therapy

To improve family systems and interpersonal dynamics, Dynamic Family Therapy LLC offers specialized Family Therapy in Honolulu. These sessions focus on communication, conflict resolution, and emotional support, guiding family members toward stronger and more meaningful connections.

Couples facing relationship challenges also benefit from focused interventions designed to enhance understanding and intimacy. Whether facing long-standing issues or new stressors, many turn to Couples Therapy in Honolulu for professional guidance and restoration.

About Dynamic Family Therapy LLC

With a mission rooted in inclusivity, education, and emotional well-being, Dynamic Family Therapy LLC continues to expand its reach throughout the island. Services are offered in a welcoming, culturally sensitive environment that honors the unique needs of every individual and family. For more information or to explore available services, visit their website.

Media Contact
Company Name: Dynamic Family Therapy LLC
Email: Send Email
Phone: (808) 909-8667
Address:99-149 Moanalua Rd #201
City: Aiea
State: HI 96701
Country: United States
Website: http://www.hidft.com/

First Choice Chiropractic Newark Offers Holistic Pain Relief and Recovery Solutions

First Choice Chiropractic, a trusted provider of chiropractic care in Central Ohio, is now offering expanded services at its Newark location. Specializing in personalized, non-invasive treatment methods, this clinic is committed to helping patients overcome pain and regain mobility through targeted, evidence-based care.

Expert Chiropractic Services in Newark

First Choice Chiropractic delivers high-quality care through a combination of advanced spinal adjustments, therapeutic exercises, and soft tissue techniques. Individuals experiencing discomfort related to auto accidents, work-related injuries, or chronic conditions may benefit from the expertise of Chiropractors in Newark, who tailor care plans to address the root causes of musculoskeletal issues.

Chiropractic Massage and Holistic Wellness

To further enhance recovery and reduce stress, First Choice Chiropractic also offers Chiropractic Massage in Newark. This service supports improved circulation, reduced muscle tension, and enhanced flexibility, making it a valuable complement to traditional chiropractic treatments. Massage therapy sessions are designed to meet the specific needs of each individual, promoting comprehensive wellness and recovery.

Trusted Newark Ohio Chiropractor

As a leading Newark Ohio Chiropractor, First Choice Chiropractic has built a reputation for professionalism, compassion, and results-driven care. The clinic combines modern techniques with a patient-first philosophy, ensuring individuals in the Newark area have access to safe and effective treatment options.

About First Choice Chiropractic (Newark):

First Choice Chiropractic (Newark) provides expert chiropractic care focused on injury recovery, pain relief, and long-term wellness. With a commitment to individualized treatment and non-invasive techniques, the clinic serves the Newark community with trusted, compassionate care designed to restore function and improve overall quality of life.

Media Contact
Company Name: First Choice Chiropractic
Contact Person: Dr. Sarar
Email: Send Email
Phone: (740) 618-7160
Address:786 W Main St
City: Newark
State: OH
Country: United States
Website: https://www.ohioinjurydoctors.com/newark-office

OutsideDepot.com Announces Major Brand Development in Home Furnishings Industry

The new brand initiative reflects the company’s ongoing focus on innovation, growth, and long-term vision in the furniture and home decor sector. With this development, OutsideDepot.com aims to strengthen its market position and adapt to changing consumer preferences, reinforcing its core values and commitment to quality and customer satisfaction.

OutsideDepot.com, a recognized name in the furniture and home decor industry, is proud to announce a significant brand evolution as it continues to deliver stylish, functional, and high end furnishings for homes of every kind. This latest development aligns with the company’s mission to elevate everyday living by offering carefully curated collections, improved customer experiences, and enhanced design inspiration across every room.

The updated brand identity includes a modernized visual aesthetic, a more intuitive shopping experience, and the expansion of product categories tailored to meet contemporary design trends and practical lifestyle needs. These updates reflect a deeper commitment to meeting the evolving demands of today’s home dwellers—from urban apartment residents to families designing their forever homes.

Through its renewed focus on craftsmanship and design, OutsideDepot.com is launching a series of exclusive furniture lines that blend aesthetic appeal with durability and value. Each collection will reflect the company’s passion for timeless design, versatile functionality, and customer-focused innovation. The rollout of these new collections will be supported by style guides, inspiration galleries, and interactive room planners to help customers create spaces that reflect their individual tastes.

In addition to expanding its product selection, OutsideDepot.com has enhanced its e-commerce platform to offer a seamless and engaging shopping experience. With improved site navigation, faster page load times, and personalized recommendations, customers will enjoy a user-friendly experience from browsing to delivery. The updated platform will also offer a responsive mobile experience, flexible payment options, and a simplified checkout process designed with convenience in mind.

Another key aspect of this brand initiative is a renewed focus on customer service excellence. OutsideDepot.com is investing in a dedicated support team, offering faster response times, comprehensive order tracking, and live design consultations for customers seeking help in furnishing their spaces. The company is also introducing a new loyalty rewards program designed to thank repeat shoppers with exclusive perks, early access to new collections, and special savings.

As part of its broader mission, OutsideDepot.com is placing an emphasis on sustainability by introducing eco-conscious product lines and packaging solutions. A growing selection of items will feature sustainably sourced materials and responsibly manufactured finishes, allowing customers to make environmentally responsible choices without compromising style or comfort.

This brand development builds on a legacy of growth for OutsideDepot.com, which has established itself as a trusted online destination for high-quality furnishings, home accessories, and decor essentials. The company’s offerings span living rooms, bedrooms, dining spaces, home offices, and outdoor areas—delivering value-driven designs that combine form, function, and affordability.

Looking ahead, OutsideDepot.com is preparing to launch a series of content-rich design resources, including blog features, trend spotlights, video tutorials, and customer room makeovers. These initiatives aim to inspire creativity and offer guidance as customers transform their houses into homes.

The rebrand marks a new chapter in the company’s story—one rooted in excellence, creativity, and connection. With this transformation, OutsideDepot.com is poised to become more than just a furniture store. It is evolving into a lifestyle destination where design meets purpose, and where every customer can find pieces that fit their life beautifully.

For more information on OutsideDepot.com and its latest brand initiative, visit www.outsidedepot.com.

About OutsideDepot.com

OutsideDepot.com is a high end online furniture and home decor retailer offering a wide selection of stylish, quality furnishings for every room. From modern sofas and timeless dining sets to space-saving storage and cozy bedroom accents, the company is dedicated to making design accessible to all. With a focus on customer satisfaction, sustainability, and quality, OutsideDepot.com continues to help customers create beautiful and functional spaces they love.

Media Contact
Company Name: Outside Depot
Email: Send Email
Country: United States
Website: https://www.outsidedepot.com

Marketing1on1 Releases Eye-Opening Guide on Ranking in AI Overviews, for Digital Marketers

Marketing1on1 has recently come out with an informative guide for digital marketers and small publishers, providing them with useful information on how to rank in AI overviews and improve their visibility in AI-generated blocks in the search engine results pages.

Los Angeles, CA – July 09, 2025 – It is no secret that online visibility is undergoing a major transformation today, with search engines like Google evolving and prioritizing AI-generated overviews at the top of SERPs. Marketing1on1, a top name in SEO and digital marketing services worldwide, has recently published a groundbreaking new guide on ranking in AI SEOoverviews, which can be eye-opening for digital marketers, globally.

This useful guide reveals how AI overviews, also referred to as AI summaries or AI snapshots work in reality. With this guide on AI overviews and small publishers, marketers can get a stepwise framework to gain top visibility for their websites and blogs in the existing search engine landscape.

“In a way, we are making it clear for marketers how the SEO rulebook is being rewritten and how to rank in AI overviews”, says a company spokesperson, “AI generated and synthesized content are replacing the traditional top-10 blue link model. Users can get answers to their queries even before they click through. Unless your content is featured in these AI summaries, your website or blog visibility is going to be at risk for sure.

What happens is that content from top ranking pages are synthesized by AI overviews. Users can find contextually smart and condensed summaries at the top of search results, when they make any query. This feature is actually aimed at improving user experience. However, for content creators, it can give rise to a dilemma. Even if they create high-quality content, it may not be noticed by users unless it enters the AI-generated block.

The latest guide of Marketing1on1 Show this safe shift in great detail It offers death proven strategies for optimizing content in a search engine where an environment where AI is taking precedence. According to this guide, ranking in the top 20 search results is important for visibility in the AI-generated blocks, with citations from reliable sources improving inclusion. It focuses on semantic recognition using schema and topic clusters, strengthening E-E-A-T signals and targeting “People Also Ask” queries, so that AI rankings can be influenced.

With AI rising in the search domain more and more, small publishers can be in for a tough time. Actually, they are facing the heat already. With platforms like Google directly summarizing content in search engine results pages, traffic to original websites or blogs is declining fast, particularly for informational websites.

According to Marketing1on1, this is the “Great Decoupling”, in which intermediary AI is cutting off creators from users in search engine platforms. Naturally, with its handy guide, this digital marketing company has created a survival manual for content creators. Going through it, creators can understand how to evolve with the changing times or risk losing their search engine visibility altogether.

In the search era of 2025, powered by artificial intelligence, the knowledge shared by the new guide of Marketing1on1 can be indispensable for marketing strategists, ecommerce business owners and independent publishers out there.

About Marketing1on1 LLC

Marketing1on1 is a top digital marketing agency based in LA, providing individuals and businesses worldwide with cutting-edge SEO, logo design, SMM, web design and many other services at competitive rates.

For further information, visit https://www.marketing1on1.com/

Media Contact
Company Name: Marketing1on1
Email: Send Email
Phone: (818) 538-4805
City: Los Angeles
State: California
Country: United States
Website: https://www.marketing1on1.com/

MSG91 Elevates WhatsApp Communication for Businesses with Scalable API Integration

MSG91 is assisting businesses to make sure that customer engagement is simple by offering a scalable WhatsApp Business API. One can connect directly to existing CRMs and websites. This allows companies to manage outreach and personalise communication using a familiar messaging channel. The API allows companies to manage customer orders, give order status, notifications, and monitor performance in real-time.

This is not just the integration of messaging. WhatsApp has now allowed businesses to enjoy two-way communication, automated campaigns, chatbot flows, and even payments. The outcome is quicker service, increased interaction, and customer satisfaction. MSG91 can generate catalogues, handle templates, bulk messages using CSV, and analyse the results using in-built analytics. The other capabilities that are enabled on the platform include Base64 file transfer, click tracking, and segmentation.

“WhatsApp is now central to how customers expect to interact. Businesses want tools that are fast, compliant, and easy to deploy. Our WhatsApp API helps them automate critical conversations and improve customer relationships without adding complexity,” said a spokesperson from the company.

WhatsApp Business API by MSG91 is already in use in various industries. A single e-commerce firm utilizes the platform to make payment reminders and delivery notifications. A healthcare chain depends on it to confirm appointments and lab reports. Chatbots are used by edtech companies to manage admissions, and service brands automate onboarding and support. In both instances, the WhatsApp API is integrated into the fundamental business processes, making response times shorter and results better. Also, with affordable whatsapp api pricing in India, it is a very good solution for all kinds of businesses.

The platform is designed to support high-volume messaging. Businesses can upload CSV files and send thousands of messages at once. Campaigns are customised and fully traceable. Click-to-WhatsApp Ads allow businesses to convert ad viewers into chat leads with zero redirection. Catalogue features turn WhatsApp into a storefront. Automated reminders and 2-way replies help close sales faster.

Each tool is integrated within the MSG91 panel. Companies are able to design and edit templates without platform switching. Opt-out options guarantee adherence to user consent laws. The system keeps delivery reports, exportable message logs, and complete audit trails.

MSG91 offers flexibility to cost and scale-sensitive businesses. From small startups to large enterprises, the API adapts based on volume, campaign type, and integration preferences. The support team assists with onboarding, configuration, and best practices. Developers have access to full API documentation, webhooks, and testing environments.

WhatsApp is only one part of the broader MSG91 offering. Clients can also use other channels, including SMS, RCS, voice calls, and email. Campaign, OTP, Hello, and Segment modules help businesses build end-to-end communication workflows. Add-ons like the URL shortener, KnowledgeBase, and support panel enhance functionality further.

The firm is very compliant and transparent. All deployments are opt-out, with reasonable prices and ethical marketing. MSG91 also adheres to GDPR and industry-specific regulations to ensure data security and customer trust.

With more businesses adopting automation and conversational tools, MSG91 is positioning itself as a complete messaging solution. The WhatsApp Business API is at the centre of this shift, helping brands meet customers where they are — in real-time, in-app, and without delay.

About MSG91

MSG91 is a WhatsApp business api provider in India that enables businesses to connect with customers using SMS, WhatsApp, email, and voice. The platform offers APIs, automation tools, and support features that help businesses build scalable messaging systems. With clients across industries and geographies, MSG91 is committed to improving communication experiences through simple, secure, and smart solutions.

Media Contact
Company Name: MSG91
Email: Send Email
Phone: +91 70490 88848
Address:Captain C.S.Nayudu Arcade 405,406 Old Palasia Road
City: Indore
State: Madhya Pradesh
Country: India
Website: https://msg91.com/in